Drug · DIN 02558351
VANFLYTA
Yes: authorized and sold in Canada
Authorized, and the company reports that it sells it in Canada.
Status Marketed since October 30, 2025; first marketed October 30, 2025.
- Drug Identification Number (DIN)
- 02558351
- Company (DIN owner)
- Daiichi Sankyo Pharma Canada LimitedToronto, Ontario, Canada
- Schedule
- Prescription
- Dosage form
- Tablet
- Route
- Oral
- Therapeutic class (ATC)
- Quizartinib L01EX11
- Class
- Human
- Record last updated
- April 22, 2026
Active ingredients
As listed in the Drug Product Database.
| Ingredient | Strength | Per |
|---|---|---|
| QUIZARTINIB (QUIZARTINIB HYDROCHLORIDE) | 17.7 MG |
Notices of Compliance
Health Canada approvals that name this DIN.
- June 9, 2025: NOC 35483New Drug Submission (NDS)
Other DINs named VANFLYTA
- DIN 02558378 · Marketed